Paul S. Changelian
Corporate Officer/Principal chez Aclaris Life Sciences, Inc.
Profil
Paul S.
Changelian is currently the Director-Biology at Aclaris Life Sciences, Inc. He previously worked as a Principal at Pfizer Inc., Vice President-Biology at Lycera Corp., and Senior Vice President-Biology at Aclaris Therapeutics, Inc. He also worked as an Assistant Professor at the University of Michigan.
Changelian holds a doctorate degree from Harvard University and an undergraduate degree from the University of Michigan.
Postes actifs de Paul S. Changelian
| Sociétés | Poste | Début |
|---|---|---|
Aclaris Life Sciences, Inc.
 Aclaris Life Sciences, Inc. Medical/Nursing ServicesHealth Services Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO. | Corporate Officer/Principal | - |
Anciens postes connus de Paul S. Changelian
| Sociétés | Poste | Fin |
|---|---|---|
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| University of Michigan | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - |
Formation de Paul S. Changelian
| University of Michigan | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ACLARIS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
Aclaris Life Sciences, Inc.
Aclaris Life Sciences, Inc. Medical/Nursing ServicesHealth Services Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO. | Health Services |